Current status and thoughts on immunotherapy with PD1/PD-L1 monoclonal antibodies for advanced lung cancer

QIAN Zhe; HU Ying; LIN Gen

doi:10.3969/j.issn.1674-3806.2024.12.03

Abstract：Lung cancer is a malignant tumor with the highest incidence and mortality rates worldwide.In recent years,immune checkpoint inhibitors represented by programmed cell death protein 1(PD1)/programmed death-ligand 1(PD-L1)monoclonal antibodies have made significant progress in the treatment of lung cancer.In advanced non-small-cell lung cancer,the immunotherapy with PD1/PD-L1 monoclonal antibodies has become a first-line standard treatment option,especially for the patients with high PD-L1 expression,in whom single-agent immunotherapy can significantly improve the efficacy and reduce adverse reactions compared with traditional chemotherapy.In addition,the combination of immunotherapy and other treatments,such as immunotherapy+chemotherapy and two immunotherapy regimens,has also been widely accepted in the treatment of non-small-cell lung cancer.For advanced small-cell lung cancer,the immunotherapy with PD1/PD-L1 monoclonal antibodies has also broken through the bottleneck of traditional first-line treatment and has significantly improved the prognosis of the patients.However,there are still many challenges in immunotherapy,such as the selection of sensitive patients,overcoming drug resistance,the choice of combination therapy,and the management of adverse reactions.In the future,the development of dual-antibody drugs and new types of immunotherapy drugs will become the key to breaking through the bottleneck of immunotherapy for lung cancer.At the same time,researches on immunotherapy in the combination therapy and the prevention and treatment of drug resistance will continue to deepen,bringing more long-term survival benefits to lung cancer patients.